HomeInsightsStock Comparison

Dr Reddys Laboratories Ltd vs Piramal Pharma Ltd Stock Comparison

Dr Reddys Laboratories Ltd vs Piramal Pharma Ltd Stock Comparison

Last Updated on: Jun 21, 2025

Key Highlights

  • The Latest Trading Price of Dr Reddys Laboratories Ltd is ₹ 1325 as of 20 Jun 15:30.
  • The P/E Ratio of Dr Reddys Laboratories Ltd changed from 25.6 on March 2020 to 18.4 on March 2024 . This represents a CAGR of -6.39% over 5 yearsThe P/E Ratio of Piramal Pharma Ltd changed from 991.5 on March 2024 to 991.5 on March 2024 . This represents a CAGR of 0.00% over 1 years.
  • The Market Cap of Dr Reddys Laboratories Ltd changed from ₹ 51797 crore on March 2020 to ₹ 102679 crore on March 2024 . This represents a CAGR of 14.67% over 5 yearsThe Market Cap of Piramal Pharma Ltd changed from ₹ 8165 crore on March 2023 to ₹ 17052 crore on March 2024 . This represents a CAGR of 44.51% over 2 years.
  • The revenue of Dr Reddys Laboratories Ltd for the Mar '25 is ₹ 9056 crore as compare to the Dec '24 revenue of ₹ 8535 crore. This represent the growth of 6.1% The revenue of Piramal Pharma Ltd for the Mar '25 is ₹ 2812 crore as compare to the Dec '24 revenue of ₹ 2233 crore. This represent the growth of 25.92%.
  • The ebitda of Dr Reddys Laboratories Ltd for the Mar '25 is ₹ 2525 crore as compare to the Dec '24 ebitda of ₹ 2427 crore. This represent the growth of 4.04% The ebitda of Piramal Pharma Ltd for the Mar '25 is ₹ 619.24 crore as compare to the Dec '24 ebitda of ₹ 366.92 crore. This represent the growth of 68.77%.
  • The net profit of Dr Reddys Laboratories Ltd changed from ₹ 1405 crore to ₹ 1586 crore over 8 quarters. This represents a CAGR of 6.27% The net profit of Piramal Pharma Ltd changed from ₹ -98.58 crore to ₹ 153.5 crore over 8 quarters. This represents a CAGR of NaN% .
  • The Dividend Payout of Dr Reddys Laboratories Ltd changed from 14.14 % on March 2020 to 15.37 % on March 2024 . This represents a CAGR of 1.68% over 5 yearsThe Dividend Payout of Piramal Pharma Ltd changed from 18.07 % on March 2022 to 3.72 % on March 2024 . This represents a CAGR of -40.95% over 3 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Dr Reddys Laboratories Ltd

  • Dr Reddy's Laboratories Limited (DRL) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.
  • Through its three businesses - Pharmaceutical Services &Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including Active Pharmaceutical Ingredients (APIs), custom pharmaceutical services, generics, biosimilars and differentiated formulations.
  • The company's major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.
  • Dr. Reddy's operates in markets across the globe.
  • Its major markets include - USA, India, Russia & CIS countries, and Europe. Dr Reddy's Laboratories Limited was incorporated in 1984 in Hyderabad.

About Piramal Pharma Ltd

  • Piramal Pharma Limited was incorporated on March 4, 2020 as a Public Limited Company and registered with the RoC. The Company offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 17 global facilities and a global distribution network in over 100 countries.
  • It includes an integrated CDMO business, CHG business and ICH business, selling over-the-counter products in India.
  • In addition, it has a joint venture with Allergan, a leader in ophthalmology in the Indian formulations market. PPL is a leading pharmaceutical company with global operations, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and global distribution network.
  • It operate under three business verticals - Piramal Pharma Solutions, an integrated contract development and manufacturing organization (CDMO) having a product suite in niche areas such as highly potent Active pharmaceutical ingredients (APIs), Finished dosage forms (FDFs), antibody drug conjugates, potent sterile injectable, hormonal oral solid dosage forms, biologics and vaccines; Piramal Critical Care, a complex hospital generics (CHG) business in the areas of inhalation anaesthesia, injectable anaesthesia and pain management, intrathecal therapy and other injectable; and India consumer healthcare (ICH) business, selling well-known OTC brands.

Dr Reddys Laboratories Ltd News Hub

News

Dr Reddys Laboratories allots Equity shares

Dr Reddys Laboratories has allotted 57,885 equity shares of Re.1/- each of the Company, fu...

Read more

16 Jun 2025 10:27

News

Dr Reddys Laboratories Ltd up for third consecutive session

Dr Reddys Laboratories Ltd is up for a third straight session today. The stock is quoting ...

Read more

12 Jun 2025 13:05

News

Dr Reddys Laboratories Ltd soars 0.07%, up for fifth straight session

Dr Reddys Laboratories Ltd gained for a fifth straight session today. The stock is quoting...

Read more

09 Jun 2025 13:00

News

Alvotech and Dr Reddy's enter into collaboration and license agreement for pembrolizumab

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manu...

Read more

05 Jun 2025 09:20

News

Dr Reddys Lab gains on global biosimilar deal with Alvotech

Keytruda, a widely used immunotherapy for various cancer types, recorded global sales of $...

Read more

05 Jun 2025 10:10

News

Dr Reddys Laboratories allots 57,840 equity shares under ESOS

Dr Reddys Laboratories has allotted 57,840 equity shares of Re.1/- each of the Company, fu...

Read more

03 Jun 2025 16:28

Piramal Pharma Ltd News Hub

News

Piramal Pharma to conduct AGM

Piramal Pharma announced that the 5th Annual General Meeting(AGM) of the company will be h...

Read more

14 Jun 2025 14:54

News

Piramal Pharma's Aurora unit completes USFDA inspection

Piramal Pharma announced that the US FDA conducted a general GMP (Good Manufacturing Pract...

Read more

02 Jun 2025 16:21

News

Piramal Pharma's Canada facility gets zero USFDA observation

According to a regulatory filing, the inspection was carried out from 26 May 2025 to 30 Ma...

Read more

02 Jun 2025 11:16

News

Piramal Pharma allots 35 lakh equity shares under ESOP

Piramal Pharma has allotted 35 lakh equity shares under ESOP on 21 May 2025. Consequent to...

Read more

21 May 2025 15:37

News

Board of Piramal Pharma recommends final dividend

Piramal Pharma announced that the Board of Directors of the Company at its meeting held on...

Read more

15 May 2025 10:18

News

Piramal Pharma's Turbhe facility successfully completes USFDA inspection

Piramal Pharma announced that the USFDA has issued an Establishment Inspection Report (EIR...

Read more

12 May 2025 12:47

SWOT Analysis Of Piramal Pharma Ltd

Strength

3

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Dr Reddys Laboratories Ltd

Strength

2

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Piramal Pharma Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Dr Reddys Laboratories Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Dr Reddys Laboratories Ltd and Piramal Pharma Ltd

Which company has a larger market capitalization, Dr Reddys Laboratories Ltd or Piramal Pharma Ltd?

Market cap of Dr Reddys Laboratories Ltd is 110,610 Cr while Market cap of Piramal Pharma Ltd is 25,926 Cr

What are the key factors driving the stock performance of Dr Reddys Laboratories Ltd and Piramal Pharma Ltd?

The stock performance of Dr Reddys Laboratories Ltd and Piramal Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Dr Reddys Laboratories Ltd and Piramal Pharma Ltd?

As of June 21, 2025, the Dr Reddys Laboratories Ltd stock price is INR ₹1325.45. On the other hand, Piramal Pharma Ltd stock price is INR ₹195.05.

How do dividend payouts of Dr Reddys Laboratories Ltd and Piramal Pharma Ltd compare?

To compare the dividend payouts of Dr Reddys Laboratories Ltd and Piramal Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions